Clinical Trials Logo

Benign Prostatic Hyperplasia clinical trials

View clinical trials related to Benign Prostatic Hyperplasia.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06380062 Completed - Clinical trials for Benign Prostatic Hyperplasia

Choline Metabolites in People With Prostate Cancer and Those With Benign Hyperplasia

Start date: January 12, 2012
Phase:
Study type: Observational

The aim of this study was to investigate plasma concentrations of one-carbon metabolites and phospholipid classes in participants with primary prostate cancer and those with benign hyperplasia. Moreover, the metabolites were studied in relation to tumor grade and age.

NCT ID: NCT06282731 Completed - Clinical trials for Benign Prostatic Hyperplasia

The Changes of Urine Growth Factors Level

Start date: May 31, 2013
Phase: Early Phase 1
Study type: Interventional

The Changes of Urine Growth Factors Level in Patients With Benigh Prostate Hyperplasia after medical treatment.

NCT ID: NCT06263049 Completed - Clinical trials for Benign Prostatic Hyperplasia

Is Ejaculation Preservation TURis the Natural Evolution of the "Gold Standard".

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

evaluation of the impact of apical urethral mucosa sparring with the urethra around the verumontanum on the ejaculatory function and early postoperative urinary incontinence

NCT ID: NCT06260917 Completed - Clinical trials for Benign Prostatic Hyperplasia

The Effect of Urinating Through the Zipper or by Pulling Down the Trousers on Uroflowmetry Parameters in LUTS

Start date: November 1, 2023
Phase:
Study type: Observational

There are many factors that affect uroflowmetry parameters. One of these is the urination position. Research has mostly focused on standing and sitting urination positions. However, those who prefer the standing position as a habit can urinate by opening the zipper or lowering the trousers. Although the effect of these two applications on uroflowmetry parameters in healthy men has been investigated in only one study, their effect on patients with lower urinary tract symptoms has not been examined.

NCT ID: NCT05803096 Completed - Prostate Cancer Clinical Trials

Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain

Start date: December 12, 2021
Phase: Phase 4
Study type: Interventional

Transrectal prostate biopsy is a commonly performed ambulatory procedure for diagnosing prostate cancer. Prostate biopsy are associated with pain or anxiety. Nitrous oxide (or laughing gas) is a well-known inhaled anesthetic which is frequently used in dental offices and for pediatric procedures to alleviate a patient's anxiety and pain. This study seeks to determine whether administration of nitrous oxide at the time of prostate biopsy will improve a patient's experience of care.

NCT ID: NCT05531344 Completed - Clinical trials for Benign Prostatic Hyperplasia

Composite Steep-pulseTreatment Device Used in Patients With Benign Prostatic Hyperplasia

Start date: August 20, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

This is a prospective, randomized, open-label, parallel-group, medication-control, superiority, multicenter clinical study trial. This study is studying the effects and safety in treating patients from nine different centers with Benign prostatic hyperplasia, employing Composite Steep-pulse(High-frequency irreversible electroporation) Treatment Apparatus. This device could cause cell irreversible electroporation, which leading necrosis of hyperplasia tissue cells. It also has the ability to prevent nerve,vessel, urethral and capsule unnecessary injury beside the ablation area. Composite Steep-pulse Treatment Apparatus will be used in patients who pass inclusion/exclusion criteria. Safety, quality of life, and urodynamic data analysis of each patient will be evaluated in each study patients.

NCT ID: NCT05494944 Completed - Clinical trials for Benign Prostatic Hyperplasia

Low Power ThULEP for Prostate Size More Than 80 gm

Start date: December 1, 2019
Phase: N/A
Study type: Interventional

Feasibility and Efficacy of lower power thulium enucleation of prostate more than 80 grams

NCT ID: NCT05422677 Completed - Clinical trials for Benign Prostatic Hyperplasia

An Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia

Start date: July 15, 2019
Phase:
Study type: Observational

In this study, BPH patients visited the institutions during the study period and the effectiveness and safety of the treatment of Tamsulosin(Hanmi Tams® Capsule) in real-practice. During the routine medical visit, according to the investigator's judgment, with diagnosis that the Tamsulosin prescription is appropriate, and after deciding to start treatment, patients with BPH who agreed to participate in the study were administered Tamsulosin. As this study is a non-interventional observational study, all subjects received prescriptions according to the routine treatment procedure, and there were no visits or procedures required according to the observational study protocol.

NCT ID: NCT05416606 Completed - Clinical trials for Benign Prostatic Hyperplasia

Prostate Bipolar Enucleation and Resection Versus Open Prostatectomy

Start date: October 1, 2020
Phase: N/A
Study type: Interventional

Benign prostatic hyperplasia (BPH) is a frequent disease in aging men accompanied by bladder outlet obstruction (BOO). Open prostatectomy (OP) is still considered the first-line treatment for more than 80 ml prostate size. In this study, a mixed technique called transurethral bipolar enucleation and resection of the prostate (TBERP) was compared to the standard open prostatectomy.

NCT ID: NCT05222841 Completed - Clinical trials for Benign Prostatic Hyperplasia

The Effectiveness of Spermotrend Food Supplement in the Treatment of Male Infertility

Start date: June 15, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

Spermotrend is a natural based product manufactured by Catalysis Laboratories. Its composition contains different essential elements for spermatogenesis: selenium, zinc and fructose. In addition, it contains L-arginine, natural precursor of nitric oxide that favors vasodilation, and pygeum africanum extract with antioxidant, antiinflammatory, antiandrogenic and antiproliferative action. Its main action resides in the control of oxidative damage to the tissues of the male reproductive system, as well as the control of correct spermatogenesis. Given that sperm quality can be altered by oxidative stress and that male infertility affects more and more people, the prevention and management of this deterioration becomes increasingly important. Therefore, to evaluate Spermotrend as a new therapy for male infertility, the investigators are going to study the safety and efficacy of this treatment in this clinical trial. RESEARCH HYPOTHESIS The treatment with Spermotrend improves the parameters of the spermatogenesis. GENERAL OBJECTIVES To evaluate the effectiveness and the safety level of the natural Spermotrend product in the treatment of male infertility. SPECIFIC OBJECTIVES - Evaluate the increase in sperm motility and concentration. - Identify the improvement in the seminal fluid volume. - Identify the positive changes in the sperm morphology. - Determine how to maintain the semen analysis in a normal range. - Describe the adverse effects. SECONDARY OBJECTIVES - Identify the improvement in urinary symptoms related with benign prostatic hyperplasia. - Identify the improvement in varicocele.